GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects

Diabetes, Obesity and Metabolism

Volumn 17, Issue 10, 2015, Pages 1007-1010

  Lin, J ^a   Hodge, R J ^b   O'Connor Semmes, R L ^c   Nunez, D J ^b  

^a Grifols Therapeutics Inc   (United States)

^b GLAXOSMITHKLINE   (United States)

^c PAREXEL INTERNATIONAL   (United States)

Author keywords

AlbudAb; GLP 1; GSK2374697; Long duration GLP 1 agonist; PYY

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GSK 2374697; PEPTIDE YY; PLACEBO; UNCLASSIFIED DRUG; GSK2374697; HYBRID PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN EXPERIMENT; LETTER; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OBESITY; POSTPRANDIAL STATE; PROTEIN SECRETION; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; BLOOD; DRUG EFFECTS; MEAL; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; AGED; BREAKFAST; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PEPTIDE YY; POSTPRANDIAL PERIOD; RECOMBINANT FUSION PROTEINS; YOUNG ADULT;

EID: 84942297706     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12533     Document Type: Letter

References (10)

1. O'Connor-Semmes RL, Lin J, Hodge RJ etal. GSK2374697, a novel albumin binding domain antibody (AlbudAb™) extends systemic exposure of exendin-4: first study in humans, PK/PD and safety. Clin Pharmacol Ther 2014; 96: 704-712.
2. Sewing S, Benardeau A, Migliorini C, Tobalina L, Sebokova E. Taspoglutide, a human once-weekly GLP-1 analogue, reduces post-challenge secretion of peptide YY and glucose-dependent insulinotropic peptide in an animal model of type 2 diabetes. Diabetologia 2009; 52(Suppl. 1): S312-313.
3. De Silva A, Salem V, Long CJ etal. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 2011; 14: 700-706.
4. Naslund E, Bogefors J, Skogar S etal. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999; 277: R910-916.
5. Sze L, Purtell L, Jenkins A etal. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab 2011; 96: E1314-1319.
6. Edwards CM, Stanley SA, Davis R etal. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155-161.
7. Dube PE, Brubaker PL. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007; 293: E460-465.
8. Engelstoft MS, Egerod KL, Lund ML, Schwartz TW. Enteroendocrine cell types revisited. Curr Opin Pharmacol 2013; 13: 912-921.
9. Engelstoft MS, Egerod KL, Holst B, Schwartz TW. A gut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metab 2008; 8: 447-449.
10. Nunez DJ, Bush MA, Collins DA etal. Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. PLoS One 2014; 9: e92494.